134 related articles for article (PubMed ID: 15113061)
21. [Improved tumor diagnosis using MRI with organ-specific contrast media. Wiesbaden, 12 May 1999].
Rofo; 1999 Jul; 171(1 Suppl):1-4. PubMed ID: 10467439
[No Abstract] [Full Text] [Related]
22. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
[TBL] [Abstract][Full Text] [Related]
23. SPIO-MRI in the detection of hepatocellular carcinoma.
Araki T
J Gastroenterol; 2000; 35(11):874-6. PubMed ID: 11085500
[No Abstract] [Full Text] [Related]
24. Clinical results with Resovist: a phase 2 clinical trial.
Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
[TBL] [Abstract][Full Text] [Related]
25. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
[No Abstract] [Full Text] [Related]
26. [Dynamic and static MRI using superparamagnetic MRI contrast medium Resovist for visualizing primary and secondary liver tumors].
Vogl TJ; Schwarz W; Hammerstingl R; Kümmel S; Balzer JO; Mack MG; Diebold T; Balzer T; Shamsi K; Bechstein WO; Schrem H; Neuhaus P; Felix R
Rofo; 1997 Sep; 167(3):264-73. PubMed ID: 9376555
[TBL] [Abstract][Full Text] [Related]
27. Real enhancement or merely increased contrast?
Chen JH
AJR Am J Roentgenol; 1997 Jan; 168(1):279-80. PubMed ID: 8976963
[No Abstract] [Full Text] [Related]
28. The role of SPIO-enhanced MRI in the detection of malignant liver lesions.
Savranoglu P; Obuz F; Karasu S; Coker A; Secil M; Sagol O; Igci E; Dicle O; Astarcioglu I
Clin Imaging; 2006; 30(6):377-81. PubMed ID: 17101405
[TBL] [Abstract][Full Text] [Related]
29. [Obsolete methods in examination of the liver with MRI].
Schadmand-Fischer S
Rofo; 1998 Dec; 169(6):679-80. PubMed ID: 9930229
[No Abstract] [Full Text] [Related]
30. Will ferumoxides-enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future.
Soyer P
Radiology; 1996 Sep; 200(3):610-1. PubMed ID: 8756902
[No Abstract] [Full Text] [Related]
31. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
[TBL] [Abstract][Full Text] [Related]
32. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
Pleger B; Beyer HK; Laufer U
Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
[No Abstract] [Full Text] [Related]
33. Dynamic T1-weighted ferumoxides enhanced MRI for imaging liver hemangiomas: preliminary observations.
Sahani D; Saini S; Sharma R; O'Malley M; Hahn P
Abdom Imaging; 2001; 26(2):166-70. PubMed ID: 11178694
[TBL] [Abstract][Full Text] [Related]
34. Quantitative assessment of iron-oxide-enhanced magnetic resonance imaging of the liver: Vessel isointensity is a potential characteristic of liver hemangiomas on late T1-weighted images.
Schmitz SA; Nikolova A; O'Regan D; Albrecht T; Hohmann J; Wolf KJ
Acta Radiol; 2006 Sep; 47(7):634-42. PubMed ID: 16950695
[TBL] [Abstract][Full Text] [Related]
35. Detection of small hypervascular hepatocellular carcinomas in cirrhotic patients: comparison of superparamagnetic iron oxide-enhanced MR imaging with dual-phase spiral CT.
Lee JM; Kim IH; Kwak HS; Youk JH; Han YM; Kim CS
Korean J Radiol; 2003; 4(1):1-8. PubMed ID: 12679628
[TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
Saini S; Edelman RR; Li W; Petersein J; Hahn PF
Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
[No Abstract] [Full Text] [Related]
37. Characterizing liver hemangiomas on ferumoxides-enhanced dynamic TI-weighted imaging: preliminary experience.
Sahani D; Saini S; Sharma R; O'Malley M; Harisinghani M; Hahn PF; Mueller PR
Acad Radiol; 2002 May; 9 Suppl 1():S255-6. PubMed ID: 12019883
[No Abstract] [Full Text] [Related]
38. Imaging of small hepatic metastases of colorectal carcinoma: how to use superparamagnetic iron oxide-enhanced magnetic resonance imaging in the multidetector-row computed tomography age?
Motosugi U; Ichikawa T; Nakajima H; Sou H; Sano M; Sano K; Araki T; Iino H; Fujii H; Nakazawa T
J Comput Assist Tomogr; 2009; 33(2):266-72. PubMed ID: 19346857
[TBL] [Abstract][Full Text] [Related]
39. Detection of colorectal liver metastases: prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography.
Lencioni R; Donati F; Cioni D; Paolicchi A; Cicorelli A; Bartolozzi C
MAGMA; 1998 Dec; 7(2):76-87. PubMed ID: 9951768
[TBL] [Abstract][Full Text] [Related]
40. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
Petersein J; Saini S; Weissleder R
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
